Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12-week, placebo-controlled study

Respirology

Volumn 17, Issue 2, 2012, Pages 379-389

  Kinoshita, Masaharu ^a   Lee, Sang Haak ^e   Hang, Liang Wen ^f   Ichinose, Masakazu ^b   Hosoe, Motoi ^c   Okino, Naoko ^c   Prasad, Niyati ^c   Kramer, Benjamin ^g   Fukuchi, Yoshinosuke ^d  

^a Nagata Hospital   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c NOVARTIS   (United Kingdom)

^d JUNTENDO UNIVERSITY   (Japan)

^e The Catholic University of Korea   (South Korea)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Asian population; bronchodilator; COPD; efficacy; indacaterol; safety

Indexed keywords

INDACATEROL; PLACEBO; SALBUTAMOL;

AGED; ARTICLE; ASIA; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; HYPERTENSION; INSOMNIA; JAPAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ADMINISTRATION, INHALATION; ADULT; AGED; BRONCHOCONSTRICTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HONG KONG; HUMANS; INDANS; INDIA; JAPAN; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; QUINOLONES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SINGAPORE; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863011714     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02107.x     Document Type: Article

References (22)

1. Regional COPD Working Group. COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology 2003; 8: 192-8.
2. Fukuchi Y, Nishimura M, Ichinose M, et al,. COPD in Japan: the Nippon COPD Epidemiology study. Respirology 2004; 9: 458-65. (Pubitemid 40179750)
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2010. [Accessed 17 Jan 2010.] Available from URL: http://www.goldcopd.com
4. The Asia Pacific COPD Roundtable Group. Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. Respirology 2005; 10: 9-17.
5. Cazzola M, Matera MG, Lotvall J,. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert. Opin. Investig. Drugs 2005; 14: 775-83. (Pubitemid 41030946)
6. Dahl R, Chung KF, Buhl R, et al,. for the INVOLVE (indacaterol: value in COPD pulmonary disease: longer term validation of efficacy and safety) study investigators. Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax 2010; 65: 473-9.
7. Chapman KR, Rennard SI, Dogra A, et al,. Long-term safety and efficacy of indacaterol, a novel long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011; 140: 68-75.
8. Donohue JF, Fogarty C, Lötvall J, et al,. for the INHANCE study investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med. 2010; 182: 155-62.
9. Feldman G, Siler T, Prasad N, et al,. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm. Med. 2010; 10: 11.
10. Kornmann O, Dahl R, Centanni S, et al,. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo controlled comparison. Eur. Respir. J. 2011; 37: 273-9.
11. Miller MR, Hankinson J, Brusasco V, et al,. Standardisation of spirometry. Eur. Respir. J. 2005; 26: 319-38. (Pubitemid 41079078)
12. Mahler DA, Jr WTJ,. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2: 99-103. (Pubitemid 40776229)
13. Jones PW,. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75-9. (Pubitemid 40776227)
14. Korn S, Kerwin E, Atis S, et al,. on behalf of the INSIST study group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir. Med. 2011; 105: 719-26.
15. Buhl R, Dunn LJ, Disdier C, et al,. on behalf of the INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur. Respir. J. 2011; 38: 797-803.
16. The National Health and Nutrition Survey in Japan. Ministry of Health, Labour and Welfare of Japan, 2004. Available from URL: http://www.nih.go.jp/ eiken/english/research/pdf/nhns2004.pdf
17. National Statistics, Health Survey for England 2004. The health of minority ethnic groups. A survey carried out on behalf of The Information Centre edited by Kerry Sproston and Jennifer Mindell. 2006. Available from URL: http://www.ic.nhs.uk/webfiles/publications/hlthsvyeng2004ethnic/ HealthSurveyForEngland161205-PDF%20.pdf
18. 1/FVC. Int. J. Clin. Pract. 2009; 63: 269-74.
19. Katsura H, Yamada K, Wakabayasi R, et al,. Gender-associated differences in dyspnea and health-related quality of life in patients with chronic obstructive pulmonary disease. Respirology 2007; 12: 427-32. (Pubitemid 47164778)
20. Gooneratne N,. Cardiopulmonary disorders affecting sleep in the elderly. In:, Butkov N, Lee-Chiong T, (eds) Fundamentals of Sleep Technology. LWW, Philadelphia, PA, 2007; 200.
21. To Y, Nishimura M, Fukuchi Y, et al,. Long-term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52-week open-labeled study. 16 (Suppl. S2): A240.
22. Donohue JF, Singh D, Kornmann O, et al,. Safety of indacaterol in the treatment of patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2011; 6: 477-92.